90-day dapivirine ring for women's HIV prevention passes its first test in Phase I study
Development of a longer-acting ring builds on the monthly dapivirine ring currently under regulatory review
Published 2021-03-09 · Original archive entry · Explore research explainers
PITTSBURGH, 9 March 2021 - If approved, the monthly dapivirine vaginal ring would be the first biomedical HIV prevention method designed specifically for cisgender women, as well as the first long-acting method. Looking to the future, researchers from the National Institutes of Health-funded END